Does Network Health Cover Prolia?

What Is Prolia and Why Does Coverage Complexity Arise?

Prolia is the brand name for denosumab, a RANK ligand (RANKL) inhibitor that Amgen manufactures as a 60 mg prefilled syringe given subcutaneously once every six months. The FDA first approved it in June 2010 for postmenopausal women at high fracture risk, then extended approval to men with osteoporosis and patients on glucocorticoid therapy (FDA label, NDA 125320).

Why Specialty Classification Matters

Because Prolia is a biologic injection, insurers including Network Health almost universally place it on a specialty drug tier. Specialty tiers carry the highest cost-sharing percentages, sometimes 20 to 33 percent coinsurance with no hard cap unless your plan has an out-of-pocket maximum that kicks in first. That single classification decision explains most of the sticker shock patients experience when they first fill the prescription.

What the Clinical Evidence Shows

The FREEDOM trial (N=7,868) showed that denosumab 60 mg every 6 months reduced new vertebral fractures by 68 percent over 36 months compared with placebo (relative risk 0.32; 95 percent CI 0.26 to 0.41; P<0.001) (Cummings SR et al., NEJM 2009). Insurers use that kind of fracture-risk reduction data to justify coverage, but they also use it to set clinical thresholds. A plan that requires a documented T-score at or below -2.5 before approving Prolia is leaning directly on the enrollment criteria from FREEDOM and similar studies.

How Denosumab Compares to Bisphosphonates in Coverage Decisions

Oral bisphosphonates such as alendronate are generic, cheap, and appear on Tier 1 or Tier 2 on almost every formulary. Network Health, like most regional and national plans, may require documented intolerance to or failure of an oral bisphosphonate before approving Prolia. That step-therapy requirement is not punitive; it reflects that alendronate 70 mg weekly has a similar vertebral fracture risk-reduction profile in head-to-head observational analyses, at a fraction of the cost (Black DM et al., JAMA 2006).

How to Check Your Specific Network Health Plan's Prolia Coverage

The only definitive answer to whether your particular plan covers Prolia is your plan's formulary document and Evidence of Coverage (EOC). Network Health offers several distinct product lines, including commercial HMO and PPO plans, Medicare Advantage, and Medicaid-managed care. Prolia coverage rules differ across these lines, sometimes substantially.

Where to Find Your Formulary

1. Log in to your Network Health member portal at networkhealth.com and search the drug formulary tool using the name "denosumab" or "Prolia."
2. Call the member services number on the back of your insurance card and ask specifically about the formulary tier and prior authorization requirements for HCPCS code J0897 (denosumab injection, 1 mg) or NDC for the Prolia prefilled syringe.
3. Ask your prescribing physician's office to run an eligibility and benefits check through their billing system before scheduling the injection.

Medicare Advantage vs. Commercial Coverage

If you have a Network Health Medicare Advantage plan, Prolia may be covered under Part B rather than Part D, because it is typically administered in a physician's office rather than self-administered. Part B coverage changes the cost-sharing structure. Under the standard Medicare Part B model, you would pay 20 percent coinsurance after the Part B deductible ($240 in 2024) with no out-of-pocket cap unless you have a Medigap supplement. Network Health Medicare Advantage plans set their own cost-sharing for Part B drugs, which may be more favorable than standard Medicare (CMS Medicare Benefit Policy Manual, Chapter 15).

Prior Authorization Requirements for Prolia Through Network Health

Prior authorization (PA) is the step where your insurer confirms that the proposed treatment meets its medical necessity criteria before agreeing to pay. For Prolia, Network Health's PA criteria are typically modeled on the American Association of Clinical Endocrinology (AACE) and the Endocrine Society's clinical practice guidelines for osteoporosis management.

Typical Documentation Network Health Requires

• A bone mineral density (BMD) report showing a T-score at or below -2.5 at the lumbar spine, femoral neck, or total hip, confirming osteoporosis by WHO criteria (WHO Scientific Group, 2007)
• A confirmed osteoporosis-related fracture (vertebral or hip) even if T-score is between -1.0 and -2.5
• Documentation of FRAX 10-year fracture probability at or above 20 percent for major osteoporotic fracture or at or above 3 percent for hip fracture, per the National Osteoporosis Foundation thresholds
• Evidence of a contraindication to or failure of an oral bisphosphonate (such as esophageal stricture, persistent GI adverse effects, or renal impairment with estimated GFR <35 mL/min/1.73 m²)
• For glucocorticoid-induced osteoporosis: documentation of prednisone at least 5 mg/day for 3 or more months or equivalent

How Long the PA Process Takes

Network Health, like other Wisconsin-based insurers subject to state insurance regulations, must render a standard PA decision within 3 business days of receiving complete documentation. Urgent requests require a response within 24 hours. Submit the PA through your prescribing physician's office; they will use Network Health's provider portal or fax the PA request form with the supporting BMD report and clinical notes.

What Happens at PA Renewal

Prolia is given every 6 months, and PA approval is often granted for 12 months (covering two injections). At renewal, your physician may need to re-attest that the treatment is ongoing and that you have not experienced a serious adverse event such as osteonecrosis of the jaw or atypical femoral fracture. The AACE 2020 guidelines note that "duration of denosumab therapy should be individualized based on patient fracture risk, response to treatment, and tolerability," which is the language insurers often borrow for renewal criteria (Camacho PM et al., Endocr Pract 2020).

What Prolia Costs With and Without Network Health Coverage

Prolia's list price is approximately $1,400 to $1,600 per injection, or roughly $2,800 to $3,200 per year. With Network Health specialty tier cost-sharing, your share could range from $100 to $600 per injection depending on your deductible status, coinsurance rate, and whether you have hit your out-of-pocket maximum.

Cost-Sharing Scenarios

| Plan Type | Typical Tier | Estimated Patient Cost Per Injection | |---|---|---| | Network Health Commercial HMO (post-deductible) | Specialty | $100 to $300 coinsurance | | Network Health Commercial PPO (pre-deductible) | Specialty | Up to list price until deductible met | | Network Health Medicare Advantage (Part B drug) | Part B 20% coinsurance | $140 to $320 per injection | | Network Health Medicaid Managed Care | Covered at low or no copay | $0 to $3 typically |

These figures are estimates. Actual costs appear on your Summary of Benefits and Coverage document.

The Amgen SupportPlus Savings Program

Amgen offers a co-pay assistance card through its SupportPlus program that may reduce out-of-pocket costs to as little as $0 per dose for eligible commercially insured patients who are not enrolled in a government program. Patients with Medicare or Medicaid cannot use manufacturer co-pay cards due to federal anti-kickback rules. For those patients, the Amgen Assist 360 program provides separate support options including free drug for qualifying low-income individuals (Amgen Assist 360 information via FDA-cleared prescribing information).

What to Do If Network Health Denies Prolia Coverage

A denial is not the end of the road. Federal law and Wisconsin state law give you specific appeal rights, and many initial denials are overturned on appeal when complete documentation is submitted.

Step 1: Understand the Denial Reason

The Explanation of Benefits (EOB) or denial letter must state the specific reason. Common reasons include:

• PA not submitted before the injection was given
• Step therapy requirement not satisfied (no documented bisphosphonate trial)
• Diagnosis code on the claim does not match covered indications (e.g., M81.0 for age-related osteoporosis vs. M81.8 for other osteoporosis)
• T-score above the plan's threshold and no fragility fracture documented

Step 2: File an Internal Appeal

You have 180 days from the date of the denial notice to file an internal appeal with Network Health. Your physician's office can submit a peer-to-peer review request, where a clinician speaks directly with Network Health's medical director to explain why Prolia is medically necessary for your specific case. Peer-to-peer overturns a meaningful share of specialty drug denials before the formal appeal process is exhausted.

Step 3: Request an External Independent Review

If Network Health upholds the denial after internal appeal, you may request an external independent review organization (IRO) review. Under the Affordable Care Act, plans must comply with IRO decisions for medical necessity denials. The IRO assigns a board-certified specialist in the relevant field (endocrinology or rheumatology for osteoporosis cases) to review your case file. The Endocrine Society's position statement on osteoporosis treatment thresholds (Watts NB et al., J Clin Endocrinol Metab 2010) provides strong supporting language for cases involving high fracture risk even when T-score criteria are borderline.

Step 4: Consider Amgen's Bridge Program

While an appeal is pending, Amgen's SupportPlus bridge program can sometimes provide Prolia at no charge on a temporary basis to prevent a treatment gap. Stopping denosumab abruptly carries real clinical risk; a 2017 analysis found that bone turnover markers rebound to above-baseline levels within 12 months of discontinuation, and multiple vertebral fractures have been reported in patients who stopped denosumab without transitioning to another agent (Cummings SR et al., J Bone Miner Res 2018).

Clinical Indications That Strengthen a Coverage Case

Not every Prolia prescription is for postmenopausal osteoporosis. Network Health's formulary covers several FDA-approved indications, and each has its own PA pathway.

FDA-Approved Indications for Prolia

• Postmenopausal women with osteoporosis at high risk for fracture (T-score at or below -2.5 or history of osteoporotic fracture)
• Men with osteoporosis at high risk for fracture
• Men receiving androgen deprivation therapy (ADT) for nonmetastatic prostate cancer at high risk for fracture
• Women receiving adjuvant aromatase inhibitor (AI) therapy for breast cancer at high risk for fracture
• Glucocorticoid-induced osteoporosis in adults at high risk for fracture who are receiving systemic glucocorticoids equivalent to at least 7.5 mg/day prednisone for at least 6 months

Each of these indications has supporting trial data. The HALT trial (N=1,468) showed that denosumab reduced vertebral fractures by 62 percent in men on ADT over 36 months (Smith MR et al., NEJM 2009). That evidence base supports the case for coverage in oncology-related bone loss scenarios, which clinicians sometimes have to make explicitly when submitting PA paperwork.

Bone Density Monitoring Before and During Therapy

The International Society for Clinical Densitometry (ISCD) recommends DXA scanning every 1 to 2 years during active pharmacologic osteoporosis treatment. Having a pre-treatment DXA on file and a follow-up DXA showing treatment response strengthens both the initial PA and any renewal request. A T-score improvement of 3 to 5 percent at the lumbar spine over 12 months is a typical response to denosumab, based on data from the FREEDOM extension study (up to 10 years of open-label follow-up, N=4,550 total) (Bone HG et al., Lancet Diabetes Endocrinol 2017).

Original Decision Framework for Network Health Prolia Coverage

The following framework summarizes the decision pathway a prescribing clinician should use to maximize the likelihood of Network Health approving Prolia on the first submission:

Step 1. Confirm the diagnosis with objective data. Order a DXA scan if one has not been done in the prior 24 months. Document the T-score at lumbar spine and femoral neck. If a fragility fracture has occurred, document it explicitly in the clinical note with imaging confirmation.

Step 2. Assess contraindications to bisphosphonates. Document estimated GFR. If GFR is <35 mL/min/1.73 m², oral bisphosphonates are contraindicated and Prolia can be the first-line agent without step therapy. Document any history of esophageal disorders or persistent upper GI intolerance.

Step 3. Complete or document failure of bisphosphonate trial. If GFR is adequate and no contraindication exists, a 6-month trial of alendronate 70 mg weekly or risedronate 35 mg weekly with documented adverse effects or lack of adherence satisfies most step-therapy requirements.

Step 4. Calculate FRAX. Use the WHO FRAX tool to document 10-year fracture probability. Attach the printed FRAX output to the PA submission.

Step 5. Use the correct ICD-10 and CPT codes.

• ICD-10: M81.0 (age-related osteoporosis without current pathological fracture), M80.00XA (age-related osteoporosis with current pathological fracture), or appropriate specific code
• HCPCS: J0897 (denosumab injection, 1 mg; bill 60 units for the 60 mg dose)
• Place of service: 11 (office) or 22 (outpatient hospital), depending on where the injection is given

Step 6. Submit calcium and vitamin D documentation. The Prolia prescribing label requires supplementation with at least 1,000 mg calcium and 400 IU vitamin D daily. Documenting that the patient is on or starting supplementation signals clinical completeness to the PA reviewer.

Alternatives If Network Health Will Not Cover Prolia

If coverage is denied and appeals are exhausted, several alternatives exist.

Oral Bisphosphonates

Alendronate 70 mg weekly and risedronate 35 mg weekly are generics available for $4 to $15 per month at most pharmacies. They cover the same osteoporosis indication and carry Tier 1 status on virtually every formulary. If your reason for wanting Prolia is convenience (one injection every 6 months vs. Weekly oral dosing), that preference alone will not satisfy a medical necessity standard.

Zoledronic Acid (Reclast)

Zoledronic acid 5 mg IV once yearly is an intravenous bisphosphonate with fracture-reduction data comparable to Prolia. The HORIZON Key Fracture Trial (N=7,765) showed a 70 percent reduction in vertebral fractures over 3 years (RR 0.30; 95 percent CI 0.24 to 0.38; P<0.001) (Black DM et al., NEJM 2007). Zoledronic acid is often covered at a lower tier than Prolia and may be approvable without step therapy.

Romosozumab (Evenity)

For patients with very high fracture risk (T-score at or below -3.5 or prior osteoporotic fracture), romosozumab 210 mg monthly for 12 months is an anabolic option. It carries its own PA requirements and a black-box warning for cardiovascular events. This is not an easier-to-cover alternative but may be appropriate when fracture risk is the primary driver.

Patient Assistance Programs

Amgen Assist 360 provides free Prolia to patients who are uninsured or underinsured and meet income eligibility criteria (generally at or below 400 percent of the federal poverty level). Your physician's office can initiate enrollment.